KFDA panel to review 9 orphan drugs to resume.

Published: 2005-12-13 06:57:00

Updated: 2005-12-13 06:57:00

9 orphan drugs including Rilutek (riluzole: Rhone poulenc-Rorer Korea) and Gleevec (Novartis Korea) seem to review their orphan drug positions again.

The KFDA planned a Central Pharmaceutical Review Council, Orphan Drug Subcommittee's meeting on Dec. 20 to review whether 9 orphan drugs having ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK